Skip to main content
SpringerLink
Log in

Effects of glucagon-like peptide-1 analog liraglutide on the systemic inflammation in high-fat-diet-induced mice

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Objective

Metabolic syndrome is a chronic-metabolic disease caused by a variety of factors, including high peripheral blood insulin levels and insulin resistance. It has been reported that GLP-1 could regulate insulin resistance. It is not known whether and how GLP-1 protects from fat-induced inflammation and immune changes. We investigated if GLP-1 alters the populations of fat-induced inflammation and immune cells and the related mechanism.

Methods

We obtained obese C57BL/6J mice by feeding them high-fat food, then treated the obese mice with GLP-1+ high-fat diet (G + Hi), normal chow diet (Nor), or high-fat diet (Hi) (n = 20 for each group) for 8 weeks. The GLP-1 receptor−/− B6 group were fed with HFD for 8 weeks (GLP-1R KO + Hi). In vivo and in vitro experiments were conducted on mice immune cells to investigate the effects of GLP-1 on the changes of the immune components and functions in obesity.

Results

We found that GLP-1 could efficiently change the CD4+ T subsets and level of cytokines in high-fat-induced mice by GLP-1 receptor. Further, these changes were correlated with a reduction in fat content and serum lipid level. Interestingly, GLP-1 could enhance the function of Tregs in vitro.

Conclusion

Our data showed that GLP-1 has an important role in shaping the CD4+ T population in high-fat-diet-induced mice by GLP-1 receptor, possibly providing a new target for the treatment of metabolic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. M.A. Nauck, J.J. Meier, Incretin hormones: their role in health and disease. Diabetes Obes. Metabol. 20(Suppl 1), 5–21 (2018)

    Article  CAS  Google Scholar 

  2. S.K. Tasci, S.A. Bingol, GLP-1 localisation and proglucagon gene expression in healthy and diabetic mouse ileum. J. Vet. Res. 62(2), 237–242 (2018)

    Article  CAS  Google Scholar 

  3. A. Itoh, J. Irie, H. Tagawa et al. GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice. J. Diabetes Complicat. 31(9), 1370–1375 (2017)

    Article  Google Scholar 

  4. G.S. Carls, E. Tuttle, R.D. Tan et al. Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes. Diabetes Care 40(11), 1469–1478 (2017)

    Article  CAS  Google Scholar 

  5. E. Grasset, A. Puel, J. Charpentier et al. A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism. Cell Metabol. 26(1), 278 (2017)

    Article  CAS  Google Scholar 

  6. Q. Li, Y. Lin, S. Wang et al. GLP-1 inhibits high-glucose-induced oxidative injury of vascular endothelial Cells. Sci. Rep. 7(1), 8008 (2017)

    Article  Google Scholar 

  7. J.P. Mayer, M.H. Tschop, R.D. DiMarchi, Once blind, now we see GLP-1 molecular action. Cell Metabol. 26(2), 289–291 (2017)

    Article  CAS  Google Scholar 

  8. D.N. McBrayer, Y. Tal-Gan, Recent advances in GLP-1 receptor agonists for use in diabetes mellitus. Drug Dev. Res. 78(6), 292–299 (2017)

    Article  CAS  Google Scholar 

  9. E. Adams, P. Genter, E. Keefe et al. The GLP-1 response to glucose does not mediate beta and alpha cell dysfunction in Hispanics with abnormal glucose metabolism. Diabetes Res Clin. Pract. 135, 185–191 (2018)

    Article  CAS  Google Scholar 

  10. C.S. Bae, J. Song, The role of glucagon-like peptide 1 (GLP1) in type 3 diabetes: GLP-1 controls insulin resistance, neuroin-flammation and neurogenesis in the brain. Int. J. Mol. Sci. 18(11), 2493 (2017)

    Article  Google Scholar 

  11. L.L. Baggio, J.R. Ussher, B.A. McLean et al. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. Mol. Metabol. 6(11), 1339–1349 (2017)

    Article  CAS  Google Scholar 

  12. D.A. Briere, A.B. Bueno, E.J. Gunn et al. Mechanisms to elevate endogenous GLP-1 beyond injectable GLP-1 analogs and metabolic surgery. Diabetes 67(2), 309–320 (2018)

    Article  CAS  Google Scholar 

  13. R. Caiazzo, J. Branche, M. Daoudi et al. Increased postprandial glucagon-like peptide-1 (GLP-1) production after endoscopic gastrointestinal bypass using the Cousin lumen-apposing stent in a porcine model. Endoscopy 50(1), 14–21 (2018)

    PubMed  Google Scholar 

  14. M.A. Sanchez-Garrido, S.J. Brandt, C. Clemmensen et al. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia 60(10), 1851–1861 (2017)

    Article  CAS  Google Scholar 

  15. U. Anyanwagu, U. Anyanwagu, J. Mamza, R. Donnelly, I. Idris, Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: a large retrospective UK cohort study. Am. Heart J. 196, 18–27 (2018)

    Article  CAS  Google Scholar 

  16. X. Cai, J. Li, M. Wang et al. GLP-1 treatment improves diabetic retinopathy by alleviating autophagy through GLP-1R-ERK1/2-HDAC6 signaling pathway. Int J. Med Sci. 14(12), 1203–1212 (2017)

    Article  CAS  Google Scholar 

  17. P. Almgren, A. Lindqvist, U. Krus, et al. Genetic determinants of circulating GIP and GLP-1 concentrations. JCI Insight. 2(21), e93306 (2017)

  18. D. Athauda, T. Foltynie, Protective effects of the GLP-1 mimetic exendin-4 in Parkinson’s disease. Neuropharmacology 136(Pt B), 260–270 (2018)

    Article  CAS  Google Scholar 

  19. S. Baba, M. Iwasa, K. Higashi et al. Antidiabetic drug alogliptin protects the heart against ischemia-reperfusion injury through GLP-1 receptor-dependent and receptor-independent pathways involving nitric oxide production in rabbits. J. Cardiovasc. Pharmacol. 70(6), 382–389 (2017)

    CAS  PubMed  Google Scholar 

  20. K. Coveleskie, L.A. Kilpatrick, A. Gupta et al. The effect of the GLP-1 analogue exenatide on functional connectivity within an NTS-based network in women with and without obesity. Obes. Sci. Pract. 3(4), 434–445 (2017)

    Article  CAS  Google Scholar 

  21. H.M. Dorton, S. Luo, J.R. Monterosso, K.A. Page, Influences of dietary added sugar consumption on striatal food-cue reactivity and postprandial GLP-1 response. Front. Psychiatry 8, 297 (2017)

    Article  Google Scholar 

  22. R. Garg, Nutritional insulin or Glp-1 receptor agonist: crossroads in the treatment of type 2 diabetes mellitus. Endocr. Pract. 23(11), 1357–1358 (2017)

    Article  Google Scholar 

  23. C. Giezenaar, N.D. Luscombe-Marsh, A.T. Hutchison, et al., Effect of age on blood glucose and plasma insulin, glucagon, ghrelin, CCK, GIP, and GLP-1 responses to whey protein ingestion. Nutrients 10(1), 2 (2017)

    Article  Google Scholar 

  24. A. Leonardini, R. D’Oria, M.A. Incalza et al. GLP-1 receptor activation inhibits palmitate-induced apoptosis via ceramide in human cardiac progenitor cells. J. Clin. Endocrinol. Metabol. 102(11), 4136–4147 (2017)

    Article  Google Scholar 

  25. X. Wang, J. Liu, C. Li, et al., Impaired secretion of active GLP-1 in patients with hypertriglyceridaemia: a novel lipotoxicity paradigm? Diabetes Metabol. Res. Rev. 34(2), e2964 (2018)

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Key Research and Development Program of Shandong Province (No. 2016GSF201012) and the Natural Science Foundation of Shandong Province (No. BS2015YY011) and the National Natural Science Foundation (No. 81500631).

Authors' contributions

LS conceived the project. SS and LS designed the experiments. SS analyzed the data and conducted experiments. SS wrote and edited the manuscript.

Author information

Authors and Affiliations

  1. Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, Shandong, China

    Sha Sha, Xiaoming Liu, Ruxing Zhao, Li Qing, Qin He, Lei Sun & Li Chen

  2. Institute of Endocrine and Metabolic Diseases of Shandong University, Jinan, Shandong, China

    Sha Sha, Xiaoming Liu, Ruxing Zhao, Li Qing, Qin He, Lei Sun & Li Chen

  3. Key Laboratory of Endocrine and Metabolic Diseases, Shandong Province medicine& health, Jinan, Shandong, China

    Sha Sha, Xiaoming Liu, Ruxing Zhao, Li Qing, Qin He, Lei Sun & Li Chen

Authors
  1. Sha Sha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoming Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ruxing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Li Qing
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qin He
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lei Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Li Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Lei Sun or Li Chen.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sha, S., Liu, X., Zhao, R. et al. Effects of glucagon-like peptide-1 analog liraglutide on the systemic inflammation in high-fat-diet-induced mice. Endocrine 66, 494–502 (2019). https://doi.org/10.1007/s12020-019-02081-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-019-02081-x

Keywords

Search

Navigation